Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | RORA | P35398 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | RORB | Q92753 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341612 | 0.89 | CCR9 (0.39) | CCR9KCNH2PGRRORARORC | |
| SCHEMBL24630688 | 0.85 | CCR9 (0.38) | CCR9KCNH2ALDH1A1HPGDALOX15 | |
| SCHEMBL24943615 | 0.76 | CCR9 (0.38) | CCR9KCNH2PGRRORARORC | |
| SCHEMBL21341616 | 0.74 | CCR9 (0.38) | CCR9KCNH2PGRRORARORC | |
| SCHEMBL21341336 | 0.73 | KCNH2 (0.38) | CCR9KCNH2ALDH1A1HPGDALOX15 | |
| SCHEMBL21341334 | 0.71 | CCR9 (0.39) | CCR9KCNH2PGRRORARORC | |
| SCHEMBL24943616 | 0.70 | CCR9 (0.33) | CCR9KCNH2PGRRORARORC | |
| SCHEMBL24944392 | 0.69 | CCR9 (0.36) | CCR9KCNH2 | |
| SCHEMBL24943811 | 0.69 | CCR9 (0.38) | CCR9ALDH1A1HPGDHSD17B10 | |
| SCHEMBL20618779 | 0.69 | KDM4E (0.39) | CCR9KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378743-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | SLC10A1, CYP7A1, FABP1 | CCR9 2594/4885KCNH2 4488/4885PGR 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.